Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record.

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials

Open access
Mercuri, Eugenio, Finkel, Richard, Montes, Jacqueline, Mazzone, Elena S., Sormani, Maria Pia, Main, Marion, Ramsey, Danielle, Mayhew, Anna, Glanzman, Allan M., Dunaway, Sally, Salazar, Rachel, Pasternak, Amy, Quigley, Janet, Pane, Marika, Pera, Maria Carmela, Scoto, Mariacristina, Messina, Sonia, Sframeli, Maria, Vita, Gian Luca, D'Amico, Adele, van den Hauwe, Marleen, Sivo, Serena, Goemans, Nathalie, Kaufmann, Petra, Darras, Basil T., Bertini, Enrico, Muntoni, Francesco, De Vivo, Darryl C. · 2016 · Neuromuscular Disorders

Abstract

The aim of the study was to establish 12-month changes in the Hammersmith Functional motor scale in a large cohort of SMA patients, to identify patterns of disease progression and the effect of different variables. 268 patients were included in this multicentric study. Their age ranged between 2.5 and 55.5 years at baseline, 68 were ambulant and 200 non-ambulant. The baseline scores ranged between 0 and 66 (mean 23.91, SD 20.09). The 12-month change was between -14 and +9 (mean -0.56, SD 2.72). Of the 268 patients, 206 (76.86%) had changes between -2 and +2 points. Ambulant and non-ambulant subjects had a different relationship between baseline values and age (p for age X ambulation interaction = 0.007). There was no association with age in ambulant subjects, while there was a significant heterogeneity at different age for non-ambulant patients (p < 0.001). The 12-month change (adjusted for baseline) was not associated with age in ambulant patients (p = 0.34), but it was significantly different among various age groups in non-ambulant patients. Our results suggest that there are different profiles of progression in ambulant and non-ambulant patients, and that age may play an important role in the progression of non-ambulant patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nmd.2015.10.006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 202

Metadata

Authors
Mercuri, E., Finkel, R., Montes, J., Mazzone, E. S., Sormani, M. P., Main, M., Ramsey, D., Mayhew, A., Glanzman, A. M., Dunaway, S., Salazar, R., Pasternak, A., Quigley, J., Pane, M., Pera, M. C., Scoto, M., Messina, S., Sframeli, M., Vita, G. L., D'Amico, A., van den Hauwe, M., Sivo, S., Goemans, N., Kaufmann, P., Darras, B. T., Bertini, E., Muntoni, F., & De Vivo, D. C.
Venue
Neuromuscular Disorders
Publisher
Elsevier BV
Published
2016-02
Volume
26
Issue
2
Pages
126-131
ISSN
0960-8966 (ISSN-L)
OpenAlex
W2189006175
Cited by
202
References
0
FWCI
5.38
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. https://app.cochat.ai/papers/10.1016/j.nmd.2015.10.006
The paper
Mercuri, E., Finkel, R., Montes, J., Mazzone, E. S., Sormani, M. P., Main, M., Ramsey, D., Mayhew, A., Glanzman, A. M., Dunaway, S., Salazar, R., Pasternak, A., Quigley, J., Pane, M., Pera, M. C., Scoto, M., Messina, S., Sframeli, M., Vita, G. L., . . . De Vivo, D. C. (2016). Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2015.10.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.